Revealing the hidden world of molecular interactions

Who we are

Depixus is a life-science tools company pioneering a cutting-edge magnetic force spectroscopy technology to unveil the intricate world of molecular interactions. Our MAGNA One instrument system can modulate and measure the forces involved in individual molecular interactions in real-time and on a massive scale. Developed and commercialized by our highly skilled team of engineers, biologists, data scientists, support staff and sales professionals in our facility, MAGNA One allows researchers to explore the dynamics of biological mechanisms. Our technology opens new pathways to decode disease mechanisms and accelerate the development of more effective therapies.

Life at Depixus

Working at Depixus

We’re always on the lookout for talented people to help bring our mission to reality. We strive to be a great employer. Working with us, you’ll be part of a collaborative and close-knit team, where not only your experience matters, but also your energy, innovations, and creativity.

Meet our leadership team & board of directors

Leadership team

Gordon Hamilton – Founder & Chief Executive Officer

Gordon Hamilton co-founded Depixus and has led the company since its inception. He has played an important role in defining the company’s vision and strategy, has helped to raise over €50m to finance its activities to-date, and has contributed to the company’s core inventions both in instrumentation and biology. Prior to Depixus, he was Medical Director at ChemoCentryx, a Californian drug-discovery company (acquired by Amgen), where he helped the company to advance its novel chemokine-targeting drugs through Phases I and II of clinical development. Before ChemoCentryx, he worked as a medical doctor in emergency medicine in the UK. He has a first-class master’s degree in Physiological Sciences from the University of Oxford, degrees in Medicine and Surgery from Imperial College School of Medicine, and an MBA from INSEAD.

Steve Allen – Chief Business Officer

Steve Allen has enjoyed a 30-year career with a track record of building a wide range of Life Science product and service companies, from start-ups to multinational corporations. Before his most recent role as CEO of DNAe, Steve held a number of leadership positions at PerkinElmer, Mettler-Toledo and LGC Forensics. Having led the acquisition of over 15 companies and the successful launch of more than fifty new scientific products and services, Steve has used his experience to assist early stage companies to make the step change from scientific innovation to commercial success. This includes the Next Generation Sequencing pioneer Solexa, where he was a Non-Executive Director and consultant, helping to scale the company to product launch and sale to Illumina. Steve has a PhD in Chemistry from the University of Nottingham.

Jimmy Ouellet – Chief Scientist

Jimmy Ouellet joined Depixus early on as a molecular biologist to develop novel sample preparations as well as reagents to produce and analyze nucleic acid molecules on the technology developed by Depixus. His work has led to multiple patents related to either sample preparation or reagents that are currently part of the Depixus’ portfolio. Prior to joining Depixus, he completed his PhD at McGill University (Montréal) followed by a post-doctoral work at ETH (Zürich). Since joining Depixus, he was involved in building the biology team and he is now in charge innovation related to new applications of the Depixus MAGNA One instrument system.

Pascale Beurdeley – Senior Vice President of Product Development

Pascale Beurdeley is the Senior Vice President of Product Development at Depixus, bringing 27 years of experience in the biotechnology industry. She has spent 13 years in executive roles, leading R&D initiatives in oncology, neurology, and infectious disease programs, with expertise in molecular biology technologies such as NGS, qPCR, and Microarray. Prior to her current role, she served as Chief Scientific Officer at PathoQuest. Before that, she held the position of Executive Director of R&D, Genomics at DIAXONHIT (formerly Exonhit Therapeutics). Pascale holds a Ph.D. from the University of Strasbourg.

Thibault Vieille – Vice President of Engineering

Thibault Vieille serves as VP of Engineering at Depixus. At Depixus, he has led the development of magnetic force spectroscopy instruments and consumables, from concept to product. Thibault joined Depixus in the company’s early days, starting as a Post-Doctoral Research Fellow at the Laboratory of Statistical Physics of the École Normale Supérieure, Paris, in the research group of the renowned biophysicists Vincent Croquette and David Bensimon. He holds a PhD in Quantum Physics from Ecole Polytechnique and master's degrees in Optical engineering and in Physics, both from Paris Saclay university.

Isabelle Belanger-Basset– Software Director

As Software Director at Depixus, Isabelle oversees the development of software solutions that support the company’s cutting-edge technology. With extensive expertise in software architecture and technology project and team management, she designs and supervises high-performance and scalable systems, meeting the stringent requirements of the industry. With 25 years of experience in software development, Isabelle plays a central role in structuring and optimizing development teams, promoting an agile and collaborative approach. Thanks to her expertise in Scrum methodologies, she ensures efficient project execution and seamless integration of software innovations within Depixus’ technological ecosystem. Committed to technological excellence and the development of advanced products, she works to ensure the reliability, performance, and adaptability of the company’s software solutions.

Board of directors

Lachlan Mackinnon – Chairman

Lachlan MacKinnon joined Oxford Sciences Innovation in 2015 as a member of the founding team. Whilst there, he made investments at the intersection of technology and biology including foundational seed investments in OMass Therapeutics, ONI, Spybiotech, Nucleome and Base Genomics which was acquired by Exact Sciences in 2020 for $410m. In 2020 he left to found his own company and joined the board of Depixus as part of the Series A.

Thibaut Roulon

Thibaut Roulon is a senior investment director at Bpifrance. He started his career as a scientist in a US biotech company developing cancer immunotherapeutics. In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies. In 2010, Bioam merged with Bpifrance Investissement, a leading French investment firm investing in SMEs and mid-Tier companies. Bpifrance manages several funds dedicated to life science investments, including InnoBio and InnoBio 2.

Thibaut is in charge of investments in life sciences companies at various stages (Seed, Venture, IPO, PIPE). He is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.

Ronald Lindsay

Ronald Lindsay is currently the Chief Executive Officer of Zebra Biologics, Inc., a company developing a disruptive new antibody generating platform. He previously served as Executive Vice President of Strategic Planning at Sequenom Inc, a company that pioneered the use of next generation sequencing for non-invasive prenatal diagnostics.

Prior to Sequenom, Ronald held a variety of senior biopharmaceutical positions, directing discovery and preclinical research efforts in cancer, neuroscience, and genomics. He has served as Vice President, Research and Development, and Chief Science Officer of diaDexus, Inc; has been a Senior Advisor at the German venture capital fund TVM Capital GmbH; was a Member of the Scientific Advisory Board of Merck Serono S.A, has held various senior management roles with Millennium Pharmaceuticals, Inc; and was a co-founder of Regeneron Pharmaceuticals, Inc., today a pharmaceutical company with a market capitalisation of ~$40bn. He began his industry career as Head of Cell Biology at the Sandoz Institute for Medical Research, University College in London. He has authored over 150 scientific articles and was recognized by the Institute for Scientific Information as one of the most highly cited neuroscientists of the 1990’s. He is also the holder of multiple patents. He has Ph.D. in Biochemistry from the University of Calgary and a B.Sc. (Honours) in Chemistry from the University of Glasgow.

Gordon Hamilton – Chief Executive Officer

Backed by...

Get in touch

Enquiry form

Send us a message via our online enquiry form

By email

info@depixus.com

Send us an email and we’ll get back to you as soon as possible

Or visit us

We’re headquartered in France, with our main offices & labs located in the Paris area. You’ll find us at: 39 Rue Louis Blanc, 92400 Courbevoie